Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men
Year: 2005
Type: editorial
Source: Osteoporosis International
Authors: Jean-Yves Reginster, Eric Abadie, Pierre Delmas, René Rizzoli, Willard Dere, Philippe van der Auwera, Bernard Avouac, Maria-Luisa Brandi, Anastasia Daifotis, Adolfo Diez-Perez, Gonzalo Calvo, Olof Johnell, Jean-Marc Kaufman, Gottfried Kreutz, Andrea Laslop, Fritz Lekkerkerker, Bruce Mitlak, Per Nilsson, John Orloff, Mary Smillie, Andrew Taylor, Yannis Tsouderos, Dominique Ethgen, Bruno Flamion
Institutions: University of Liège, Lyon 1 Université, Inserm, World Health Organization, University Hospital of Geneva, Amgen (United States), F. Hoffmann-La Roche AG, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, University of Florence, Merck & Co., Inc., Rahway, NJ, USA (United States), Universitat Autònoma de Barcelona, Hospital Del Mar, Hospital de Sant Pau, Ghent University Hospital, Federal Institute for Drugs and Medical Devices, Universität Innsbruck, Medicines Evaluation Board, Eli Lilly (United States), Medical Products Agency, Teva Pharmaceuticals (United Kingdom), Pfizer (United Kingdom), Servier (France), Institut de Recherches Internationales Servier (France), GlaxoSmithKline (United States), University of Namur
Language: English
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1968628170